middle.news
Prescient Therapeutics Opens First US Site for PTX-100 CTCL Trial – What’s Next?
9:17am on Wednesday 16th of July, 2025 AEST
•
Healthcare
Read Story
Prescient Therapeutics Opens First US Site for PTX-100 CTCL Trial – What’s Next?
9:17am on Wednesday 16th of July, 2025 AEST
Key Points
First US clinical site opened at VCU Massey Comprehensive Cancer Center
Adds to ongoing recruitment of 4 patients across 3 Australian sites
PTX-100 targets relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL)
FDA granted orphan drug and fast track designations for PTX-100
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE